Stay updated with breaking news from Vr Adviser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its target price boosted by equities researchers at Jefferies Financial Group from $75.00 to $128.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside […]
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday. A number of other research firms also recently weighed in on ADVM. Chardan Capital reissued a “buy” rating and set a $4.00 […]
Needham & Company LLC reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $30.00 target price on the stock. Other equities analysts have also issued research reports about the stock. Oppenheimer increased their target price […]
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […]
HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2024 earnings at ($0.83) EPS, Q2 2024 earnings at ($0.83) […]